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Abstract
Background: In streptozotocin-injected rats (STZ-rats), we previously demonstrated a role for angiotensin II (AT-II) in cardiac
remodelling and insulin resistance partially counteracted by in vivo treatment with losartan, an AT-II receptor antagonist.
We now aimed to investigate the effect of treating diabetic STZ-rats with losartan on diabetes vascular response to
vasoconstrictors.
Methods: Male Wistar rats were randomly divided in four groups, two of them were assigned to receive losartan in the drinking
water (20 mg/kg/day) until the experiment ending (3 weeks afterward). After 1 week, two groups, one of which receiving
losartan, were injected in the tail vein with citrate buffer (normoglycemic, N and normoglycemic, losartan-treated, NL). The
remaining received a single injection of streptozotocin (50 mg/kg in citrate i.v.) thus becoming diabetic (D) and diabetic losartan-
treated (DL). Plasma glycaemia and blood pressure were measured in all animals before the sacrifice (15 days after diabetes
induction).
In aortic strips isolated from N, NL, D and DL rats we evaluated i) the isometric concentration-dependent contractile response
to phenylephrine (Phe) and to AT-II; ii) the RhoA-kinase (ROCK1) activity and expression by enzyme-immunoassay and
Western blot respectively.
Key results: The concentration-dependent contractile effect of Phe was similar in aortas from all groups, whereas at all
concentrations tested, AT-II contraction efficacy was 2 and half and 1 and half times higher in D and DL respectively in
comparison with N and NL. AT-II contracture was similarly reduced in all groups by AT-II receptor antagonists, irbesartan or
irbesartan plus PD123319. HA-1077 (10 μM), an inhibitor of ROCK1 activity, reduced AT-II efficacy (Δmg/mg tissue w.w.) by -
3.5 ± 1.0, -4.6 ± 1.9, -22.1 ± 2.2 and -11.4 ± 1.3 in N, NL, D and DL respectively). ROCK1 activity and expression were higher
in D than in N/NL and DL aortas.
Conclusion and implications: Aortas isolated from STZ-rats present hyper-contracture to AT-II mainly dependent on the
up-regulation of ROCK1 expression/activity. In vivo losartan treatment partially corrects AT-II hyper-contracture, limiting the
increase in ROCK1 expression/activity. These data offer a new molecular mechanism supporting the rationale for using losartan
in the prevention of diabetic vascular complications.
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Angiotensin II (AT-II), one of the effectors of the renin-
angiotensin system, is among the major mediators of vas-
cular remodelling [1]. At this site, AT-II promotes short-
and long-term metabolic and functional changes, mostly
by activating the type 1 receptor (AT1) located at smooth
muscle cells (VSMCs). Besides being a potent contractile
agent, AT-II triggers pro-inflammatory, hypertrophic [2],
fibrotic and metabolic effects which include production
of reactive oxygen species (ROS) [3], insulin resistance
[4], extracellular matrix protein deposition [1,5-7], stimu-
lation of cell migration and differentiation [8]. Among the
intracellular signals, AT1 activation increases calcium lev-
els and activates several kinases including the RhoA-
kinase (ROCK1) pathway by recruiting its upstream acti-
vator, the small GTPase RhoA protein [1,9]. The target
event of ROCK1 cascade is the phosphorylation of the
myosin light chain phosphatase (MYPT1), a process that
prolongs myosin light chain (MLC) activation [10,11],
thus sustaining smooth muscle contraction [11,12]. Inhi-
bition of MYPT1 by ROCK1 activation is one of the mech-
anisms thought to be responsible for Ca2+ sensitization of
smooth-muscle contraction [9,13]; even if other kinase
activities, (i.e. zipper-interacting protein kinase, ZIP;
integrin-linked kinase; ILK; dystrophia myotonica kinase;
DMK) can inhibit MYPT1 [14-16]).
Interestingly, AT-II not only activates the RhoA/ROCK1
pathway but can also control the expression level of pro-
teins involved in the system. Up-regulation of RhoA/
ROCK1 has been described in isolated VSMCs exposed to
AT-II [17,18] and in the aorta of AT-II infused rats [19,20],
thus suggesting paracrine effects of AT-II on its intracellu-
lar signalling.
Increasing tissue levels of AT-II are found in experimental
diabetes [21] where, together with hyperglycemia, are
retained critical and initiating factors for the development
of complications based on the so-called "vascular dys-
function" (endothelial and smooth muscle dysfunction),
a condition modifying the function (hyper response to
vasoconstrictors) and the metabolism (onset of insulin
resistance and increase of oxidative stress) of the vascular
bed. Up-regulation of ROCK1 activity has been demon-
strated in the vasculature of insulin-resistant animals
independently of the experimental model studied [22,23]
whereas hyperglycemia "per se" increases ROCK1 activity
in isolated vascular cells [24]. Therefore, high AT-II and
hyperglycemia, may synergistically increase the activity of
the biochemical machinery functionally coupled to mus-
cle contraction. This implies that AT-II and hyperglycemia
might play a determinant role in priming diabetes VSMCs
dysfunction.
In streptozotocin-injected rats (STZ-rats), a widely used
experimental model for the study of diabetes-related car-
diovascular complications, the extent of the vascular dys-
function depends on the duration of the pathology [25].
We have previously reported that STZ-rats, 2 weeks after
injection, present typical diabetes-related cardiac electro-
physiological remodelling and insulin resistance [26].
Interestingly, in vivo treatment of diabetic rats with losar-
tan, an antagonist of AT- II type 1 receptors, prevented
both the electrophysiological and the metabolic altera-
tions, without affecting hyperglycemia. These results con-
firmed that selective AT1 antagonists represent useful
tools for investigating AT-II roles in priming diabetes
complications.
In the present study we aimed to extend our previous
observations investigating whether aortas from "early"
diabetic rats, show hyper-response to vasoconstrictors
including Phe and AT-II and the molecular mechanism
underlying this effect. To this aim we studied the func-
tional response to Phe and AT-II in strips prepared from
aortas isolated from 2-week STZ-rats "in vivo" treated and
not treated with losartan (20 mg/kg/day-1). By using this
pharmacological strategy, we aimed to investigate the role
of AT-II type 1 receptor in the development of vascular
hyperreactivity dependent on hyperglycemia. In this
respect, other approaches such the use of angiotensin con-
verting enzyme inhibitors (ACE-I) could be misleading,
since these molecules can influence other important vas-
cular regulatory pathways independently from their
inhibitory effect on AT-II formation.
We demonstrate that an in vivo losartan treatment reduces
vascular hyper-reactivity to AT-II, that according to our
data, is mainly dependent on an increase in the RhoA/
ROCK1 pathway.
Methods
All of the experiments were carried out in accordance with
the European Communities Council Directive of 24
November, 1986 (86/609/EEC) for experimental animal
care.
Wistar rats aged 12–14 weeks (Charles River, Calco [LC],
Italy) were randomly divided into four groups (see below
for description) and allowed free access to standard dried
chow diet and water whose consumption was monitored
daily.
Two groups of rats were assigned to receive losartan in the
drinking water (20 mg/kg/day) until the end of the exper-
iment (3 weeks afterward). After 1 week, two groups, one
of the two receiving losartan were injected in the tail vein
with citrate buffer pH 4.5 (normoglycemic, N and normo-
glycemic, losartan-treated, NL). The other two groups
received a single injection of STZ (50 mg/kg in citrate
buffer pH 4.5). According to our previous results [26] wePage 2 of 10
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injection and only those rats whose glycaemia was higher
than 14 mM were considered diabetic and included in our
schedule of treatment (diabetic, D and diabetic, losartan-
treated, DL, a total of 40 rats). The losartan concentration
was adjusted according to body weight and water con-
sumption to maintain a dosage of 20 mg/kg/day [26] and
the treatment was interrupted 24 h before sacrificing.
Animals were put in metabolic cages and fasted overnight
with free access to water before the sacrifice.
Blood pressure measurement
Diastolic and systolic blood pressure were measured the
day before sacrifice in conscious rats using BP-2000 (Vis-
itech Systems, Apex, USA) a non-invasive computerised
system for recording blood pressure from tails of rodents.
Functional studies on rat thoracic aortas
The thoracic aorta was rapidly dissected out and placed in
ice-cold, oxygenated (5% CO2 in O2) Krebs-Henseleit
solution (K-H) of the following composition (mM): 110
NaCl, 25 NaHCO3, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 11
D(+)glucose, 2.5 CaCl2. It was then cleaned of loosely
adhering fat and connective tissue, cut into helical strips,
2 mm in width and 20 mm in length, and placed in an
organ bath of 2 ml volume [27]. Then, strips were incu-
bated with pre-warmed, oxygenated K-H (37°C for at least
60 min), the resting tension being set at 0.7 g. After equi-
libration, cumulative concentration-response curves of
phenylephrine (Phe) were performed. At the sub-maximal
Phe concentration of 100 nM, the relaxing concentration-
dependent effect of acetylcholine was tested [28]. After
washings, AT-II concentration-response curves were per-
formed on 100 nM Phe pre-contracted strips. The pharma-
cological modulation of AT-II contracture was
investigated in aortic strips perfused for 30 min at 37°C
with 1 μM irbesartan or 1 μM irbesartan plus 1 μM
PD123319 (type 1 and type 2 AT-II receptor antagonists
respectively) or 10 μM HA-1077, an inhibitor of type 1
RhoA kinase (ROCK1) activity [29].
At the end of the experiments, strips were rinsed with K-H
solution for 10 min at 37°C, removed from apparatus,
blotted on filter paper and weighted. Contraction was
expressed either as mg of contractile force for mg of wet
tissue weight (mg/mg tissue w.w.) or as a percentage of
100 nM Phe contracture (100%) as indicated.
Acetylcholine, AT-II, HA-1077, PD123319 and Phe were
obtained from Sigma-Aldrich, St. Louis, MO, USA. All
other reagents were of analytical grade.
ROCK1 expression level in rat aorta homogenates
The abdominal aorta from rats belonging to the different
groups was isolated, cleaned and washed in cold saline
solution (0.9% NaCl), and frozen in liquid nitrogen. Aor-
tic samples were rinsed, weighed and homogenized (1
mg/ml) in lysis buffer of the following composition (in
mM): 50 Tris·HCl pH 7.5, 1 EDTA, 150 NaCl, 1 Na3VO4,
10 NaF and complete protease inhibitor cocktail tablet
(Sigma-Aldrich, St.Louis, MO, USA. The homogenate was
centrifuged (1,000 × g × 10 min at 4°C) to remove cell
debris. The resulting supernatant was frozen at -80°C for
later analysis by SDS-PAGE and immunoblotting. The
protein concentration of the crude lysate was determined
by the BCA protein assay reagent kit (Pierce, ROCK1eford,
IL, USA). Proteins separated on a 4–12% (w/vol) acryla-
mide gel (Nu-Page Gel, Invitrogen, Milan, Italy) were
transferred to polyvinylidene difluoride membranes and
probed with mouse anti-rabbit ROCK1 polyclonal anti-
bodies (1:200 dilution; St. Cruz Biotechnology Inc., CA,
USA) or with polyclonal anti-rabbit actin (1: 1000 dilu-
tion; Sigma-Aldrich, St. Louis, MO, USA) overnight at
4°C.
After extensive washings, a goat anti-rabbit peroxidase
conjugated antibody was added (1:2000 dilution; Sigma-
Aldrich, St. Louis, MO, USA) and immunodetected bands
were visualized by ECL. Densitometric analysis of autora-
diographic bands were referred to actin expression taking
into account the size and the area of the band (Scion soft-
ware Image Corp).
Determination of ROCK1 Activity
Aortas were rinsed, weighed, frozen in liquid nitrogen and
homogenized (3 mg/ml) in lysis buffer (see above for
composition). Homogenates were then centrifuged
(30.000 × g × 30 min) and the resulting supernatant was
used as enzymatic source of ROCK1.
Kinase activities were estimated in each sample by a non
isotopic ELISA test (Cyclex Co, Ltd; Nagano, Japan),
according to the manufacturer's instructions. For each
sample, the optimal dilution (from 1:5 to 1:40) was estab-
lished to obtain a maximal optical density (OD). Thereaf-
ter, each supernatant was pre-incubated for 30 min in the
absence (total kinase activities, e. i. zipper interacting pro-
tein kinase, ZIP, dystrophia myotonica protein kinase
DMK, integrin-linked kinase, ILK and ROCK1) or in the
presence with either 10 μM HA-1077 or 1 μM Y-27632
[30] purchased by Sigma-Aldrich, St. Louis, MO, USA),
two inhibitors of ROCK1 kinase activity. The difference
between the OD at 450 nm measured in the absence and
in the presence of ROCK1 inhibitors was calculated and
referred to as ROCK1 activity. Each sample was assayed in
duplicate.
Results are expressed as Arbitrary Units (A.U.) i.e. the OD
at 450 nm normalized to the protein content of each orig-
inal supernatant.Page 3 of 10
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Values are presented as the mean ± SEM and analysed
with one-way ANOVA followed by Bonferroni's t test.
Effective concentrations at 20%, 50% and 80% of the
maximum response (EC20, EC50 and EC80 respectively) for
each AT-II concentration response curve was calculated
using Origin Microcal® (version 7) program by extrapolat-
ing experimental points with a sigmoidal curve. A P < 0.05
was considered as significant.
Results
Characterization of animal groups
Two weeks after STZ (50 mg/kg) injection, rats from
groups D and DL showed a significant increase in water
consumption, plasma glycemia and a marked reduction
in body and heart weight vs. citrate-injected rats (group N
and NL). Therefore, animals from groups D and DL were
considered diabetic. No change in the heart weight-to-
body weight ratio, an index of cardiac hypertrophy was
observed (Table 1). Losartan treatment did not modify
any of the parameters observed either in NL or in DL
group.
Blood pressure levels in the different groups of animals
As shown in Table 2, the animals belonging to the differ-
ent groups had similar BP values irrespective of the pres-
ence of diabetes. Moreover, losartan treatment did not
modify BP either in NL or in DL groups.
The effect of phenylephrine and acetylcholine in all animal 
groups
Aortas isolated from rats belonging to the different groups
showed a similar contractile response to Phe. As illus-
trated in Figure 1 (panel A), cumulative concentration-
response curves of Phe were superimposable in the full
range of concentrations tested (1–1000 nM) and it
reached its maximal response at 1000 nM in all groups.
In aortas pre-contracted with the sub-maximal Phe con-
centration of 100 nM, acetylcholine (from 0.1 to 1 μM)
induced a similar extent of relaxation, suggesting that all
the preparations conserved a functionally active endothe-
lial layer (Figure 1B).
The contractile effect of angiotensin II in N 
(normoglycemic) and D (diabetic) groups
AT-II concentration-response curves were performed on
100 nM Phe pre-contracted preparations. AT-II further
increased the contraction in aortas isolated from each
experimental animal group (Figure 2). In particular, the
AT-II contracture was higher in D than in N group in the
concentration range from 10 to 30.000 nM (P < 0.001)
within the experimental groups reaching at the maximal
concentration, an effect that was 2.5 times higher in group
D than in aortas from group N. Notwithstanding these
differences in contraction efficacy, similar values of EC20,
EC50 and EC80 were calculated for AT-II (Table 3).
The contractile effect of angiotensin -II in normoglycemic 
and diabetic rats treated with losartan (groups NL and DL)
The AT-II concentration-response curve measured in aor-
tas from group NL was comparable to that obtained in the
N group (Figure 2), indicating that in vivo losartan treat-
ment did not affect the in vitro AT-II response, thus exclud-
ing interference by losartan pharmacokinetic on AT-II
contraction.
On the contrary, in DL aortas, AT-II contractile effect was
lower than that measured in aortas from D group in the
range from 100 to 30.000 nM (P < 0.001, Figure 2). At this
latter concentration, the AT-II contractile effect was signif-
icantly decreased from +353.3% of group D to +268.8%
in group DL (P < 0.001 vs. D), a value which remained
higher than that measured in groups N and NL (P <
0.001).
The analysis of concentration-response curves indicates
that the potency (nM) of AT-II contraction at 20, 50 and
80% of its maximum effect did not change significantly (P
> 0.05) among the experimental groups (Table 3),
whereas the contractile efficacy of AT-II (intrinsic activity)
was drastically increased in D and to a less extent in DL.
Identification of angiotensin-II receptor subtypes involved 
in the AT-II contraction
To evaluate the involvement of AT1 and type 2 receptors
(AT2) on AT-II effect, rat aortas pre-contracted with Phe
Table 1: Metabolic characteristics of normoglycemic (group N), normoglycemic, in vivo losartan treated (group NL), diabetic (group 
D) and diabetic, in vivo losartan treated (group DL) rats.
Groups Plasma Glycemia
(mM)
Daily Water 
Consumption (ml)
Daily Food Intake
(g)
Body Weight
(g)
Heart Wet 
Weight
(mg)
Heart Weight/
Body Weight
(mg/g)
N (n = 7) 7.0 ± 0.014 29.9 ± 2.2 17.9 ± 0.8 262.1 ± 10.1 993.8 ± 37 3.8 ± 0.2
NL (n = 7) 9.0 ± 0.033 29.3 ± 1.6 19.4 ± 0.5 254.7 ± 9.1 951.3 ± 36 3.7 ± 0.1
D (n = 14) 20.0 ± 0.18* 133.8 ± 6.8* 28.6 ± 0.9* 217.6 ± 5.4* 806.5 ± 33^ 3.7 ± 0.1
DL (n = 12) 18.7 ± 0.25# 130.1 ± 8.6# 27.3 ± 1.4# 207.5 ± 10.2# 851.5 ± 60 4.1 ± 0.4
Values presented are the mean ± SEM of the indicated number of rats (n). P < 0.001 vs. N; # P < 0.001 vs. NL; ^P < 0.01 vs. N. Wistar rats aged 12–
14 weeks were randomly assigned to the different groups.Page 4 of 10
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sartan or irbesartan plus PD123319 (both at a concentra-
tion of 1 μM) before performing AT-II cumulative
concentration-response curves.
As shown in Figure 3, in the presence of irbesartan, the AT-
II maximal contracture was reduced by about 50% in all
groups.
The contemporaneous presence of both receptor antago-
nists, irbesartan plus PD123319, did not completely abol-
Table 2: Blood pressure levels and heart rate of normoglycemic 
(group N), normoglycemic, in vivo losartan treated (group NL), 
diabetic (group D) and diabetic, in vivo losartan treated (group 
DL) rats.
Blood Pressure
(mmHg)
Heart Rate
(beats/min)
Groups Systolic Diastolic
N 139.2 ± 16.8 110.6 ± 2.9 393.6 ± 10.4
NL 144.0 ± 4.4 112.4 ± 5.5 385.4 ± 8.2
D 145.0 ± 8.1 119.9 ± 10.9 382.2 ± 10.3
DL 139.7 ± 6.0 99.4 ± 9.6 370.7 ± 4.2
Values are the mean ± SEM of 6 animals.
Effect of phenylephrine (panel A) and acetylcholine (panel B) on aortic strips isolated from normogly mi  (group N), nor-moglycemic  viv  losartan treated ( roup NL), diabetic (group D) and diabe ic in vivo losartan tr ated (grou  DL)ratsFigure 1
Effect of phenylephrine (panel A) and acetylcholine 
(panel B) on aortic strips isolated from normoglyc-
emic (group N), normoglycemic in vivo losartan 
treated (group NL), diabetic (group D) and diabetic 
in vivo losartan treated (group DL) rats. Cumulative 
concentration-response curves of agonists were performed 
on thoracic aortic strips stretched to 0.7 g resting tension 
with an endothelial-intact layer. Values are the mean ± SEM 
of at least 4 experiments. Panel A) phenylephrine contrac-
tion. Panel B) acethylcholine effect was evaluated on 100 nM 
phenylephryne (Phe) pre-contracted thoracic aortic strips 
(100% of contraction).
1 10 100 1000
0
5
10
15
20
25
Acetylcholine (μM)
A
 Group N
 Group NL
 Group D
 Group DL
Co
nt
ra
ct
io
n 
(m
g /
 m
g t
iss
ue
 w
.w
.) 
Phenylephrine (nM)
0
20
40
60
80
100
120
1.00.750.50.250
Co
nt
ra
ct
io
n 
(%
 10
0 n
M
 Ph
e) 
B
Table 3: Effective concentration (EC, nM) at 20%, 50% and 80% of 
maximum angiotensin II contracture in aortas isolated from 
normoglycemic (group N), in vivo losartan treated 
normoglycemic (group NL), diabetic (group D), and in vivo 
losartan treated diabetic rats (group DL) in control condition 
and in the presence of irbesartan 1 μM and 1 μM irbesartan plus 
1 μM PD123319.
EC 20% (nM)
N 3.4 ± 0.77 3.2 ± 0.67 NC
NL 3.3 ± 0.50 4.7 ± 0.72 NC
D 4.4 ± 0.81 4.7 ± 1.01 3.5 ± 0.86
DL 3.6 ± 0.70 4.0 ± 0.88 4.1 ± 0.90
EC 50% (nM)
N 22.4 ± 3.88 22.1 ± 3.47 NC
NL 19.8 ± 1.16 28.1 ± 9.79 NC
D 19.6 ± 2.22 18.3 ± 2.49 23.2 ± 3.06
DL 22.7 ± 2.10 25.9 ± 4.85 18.3 ± 2.14
EC 80% (nM)
N 106.6 ± 19.64 121.9 ± 21.30 263.8 ± 68.43
NL 117.8 ± 27.60 128.1 ± 5475 170.7 ± 11.02
D 118.4 ± 39.79 117.8 ± 30.41 215.5 ± 81.48
DL 98.5 ± 29.96 160.1 ± 18.72 277.6 ± 99.14
From each curve, the EC20%. EC50% and EC80% were calculated by 
fitting experimental points with a sigmoidal extrapolation. Values are 
the mean ± SEM of at least 4 fittings for each experimental group. NC 
= not calculated
The effect of angiotensin-II in aortic strips isolated from nor-moglyc mic (group N), ormoglycemic in viv  losartan treat d (gr up NL), diabetic (group D) and in vivo losartan diabetic rats (group DL)Figure 2
The effect of angiotensin-II in aortic strips isolated 
from normoglycemic (group N), normoglycemic in 
vivo losartan treated (group NL), diabetic (group D) 
and in vivo losartan treated diabetic rats (group DL). 
Cumulative concentration-response curves of angiotensin II 
(bolus) were performed on 100 nM phenylephryne (Phe) 
pre-contracted thoracic aortic strips stretched to 0.7 g rest-
ing tension with an endothelial-intact layer. Values are the 
mean ± SEM of 4 experiments. ***P < 0.001 vs. N and NL; 
§§§P < 0.001 vs. DL
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estimated as 18.9 ± 6.17 in N, 20.2 ± 2.75% in NL, 28.9%
± 4.4 in D and 34.6 ± 4.99% in DL was observed (P > 0.05
not significant; Figure 3). Notwithstanding this, AT-II
potency (nM) at 20, 50 and 80% of its maximum effect
was not significantly different from normo (N and NL) to
hyperglycaemic (D and DL) aortas (Table 3).
Interestingly, the pre-incubation of aortas with PD123319
in the absence of irbesartan did not produce neither a
reduction or an increase of AT-II maximum effect.
Angiotensin-II hyper-contracture in diabetic rat aorta is 
reduced by a ROCK1 inhibitor
All the evidence collected so far suggested that the AT-II-
augmented contraction observed in aortas from groups D
and DL could depend on an enhancement of some intra-
cellular transduction pathways. Among the possible tar-
gets we explored the involvement of the RhoA/ROCK1
signalling pathway. To this aim, cumulative concentra-
tion-response curves of Phe and then of AT-II were carried
out in aortas pre-incubated (30 min) in the absence or in
the presence of 10 μM HA-1077, a concentration currently
The effect of irbesartan and irbesartan plus PD123319 on angiotensin-II induced contraction in aortic strips isolated from nor-moglyc mic (N), in vivo losartan treated normoglycemic (NL), diabetic (D) and in vivo losartan treated diabet c r s (DL)Figure 3
The effect of irbesartan and irbesartan plus PD123319 on angiotensin-II induced contraction in aortic strips 
isolated from normoglycemic (N), in vivo losartan treated normoglycemic (NL), diabetic (D) and in vivo losar-
tan treated diabetic rats (DL). Cumulative concentration-response curves of angiotensin-II (bolus) were performed on 100 
nM phenylephrine (Phe) pre-contracted thoracic aortic strips stretched at 0.7 g resting tension with an endothelial-intact layer 
and pre-incubated with 1 μM irbesartan or 1 μM irbesartan plus 1 μM PD123319. The contraction obtained with 100 nM Phe 
was set as 100%. Values are the mean ± SEM of 4 experiments. Concentration-response curves of angiotensin II were signifi-
cantly (at least P < 0.05) reduced by irbesartan in aortas from all groups. At condition of irbesartan plus PD123319, angi-
otensin-II contraction was reduced further (at least P < 0.05). For the clarity, significant level marks are omitted from the 
figure.
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ROCK1 activity.
The presence of HA-1077 did not affect the contraction
produced by Phe which remained similar in N, NL or D
and DL groups. On the contrary, HA-1077 significantly
reduced the contracture of AT-II in D and DL at all the
concentrations tested, while it did not affect the AT-II con-
centration-response curves in N and NL aortas. As shown
in Figure 4 (insert) at the highest concentration (1000
nM), AT-II contraction was reduced (Δ mg mg-1 tissue w.
w.) by -3.5 ± 1.07 in N (n = 4), -4.6 ± 1.75 in NL (n = 4),
-22.1 ± 2.25* in D (n = 4), and -11.4 ± 1.32§ in DL (n = 4;
Figure 4, (insert); *P < 0.05 vs. N, NL and DL; §P < 0.05 vs.
N and D). It is worth noting that in the presence of HA-
1077, the AT-II concentration-response curves in group D
and DL become indistinguishable from those obtained in
groups N and NL (Figure 4).
Losartan treatment reduced ROCK1 enzyme activity
To further investigate the role of ROCK1 in diabetic aorta
hypercontractility, we measured the MYPT1 phosphoryla-
tion, the major target of ROCK1 cascade, as indicative of
ROCK1 phosphorylation activity. Since MYPT1 phospho-
rylation can be performed by several kinases, ROCK1
involvement was calculated by running experiments in
the absence and in the presence of two ROCK1 specific
inhibitors: HA-1077 (10 μM) and Y-2763 (1 μM). The dif-
ference between the total MYPT1 phosphorylation and
residual (ROCK1 inhibitor insensitive) levels, provided
an estimation of the ROCK1 activity
Our result show that MYPT1 phosphorylation level was
higher in D aortas in comparison with those in N, NL and
DL. When ROCK1 inhibitors (HA-1077 and Y-27632)
were used, MYPT1 phosphorilation was significantly
reduced only in D (Table 4) but not in N, NL and DL.
Interestingly enough, the extent of the inhibitor insensi-
tive MYPT1 phosphorylation gained similar values in all
groups, thus suggesting that ROCK1 activity was a pre-
Table 4: Kinase-dependent MYPT1 phosphorylation (phospho-treonine) in aortic samples from normoglycemic (group N), 
normoglycemic in vivo losartan treated (group NL), diabetic (group D) and diabetic in vivo losartan treated (group DL) rats.
MYPT1 phosphorylation (Arbitrary Units)
Groups No drug addition +HA-1077 + Y-27632
N 2.02 ± 0.27 1.19 ± 0.10
(Δ: 0.83 ± 0.18)
0.72 ± 0.068
(Δ: 1.3 ± 0.136)
NL 1.99 ± 0.135 0.99 ± 0.05
(Δ: 1.0 ± 0.3)
0.56 ± 0.03
(Δ: 1.43 ± 0.29)
D 3.4 ± 0.18***,§§ 0.47 ± 0.109
(Δ:2.92 ± 0.28***;§§
0.72 ± 0.04
(Δ: 2.67 ± 0.25*)
DL 2.17 ± 0.083 0.52 ± 0.171
(Δ: 1.65 ± 0. 24)
0.63 ± 0.039
(Δ: 1.55 ± 0.11)
***P < 0.001 vs. N and NL; §§P < 0.01 vs. DL; *P < 0.05 vs. N, NL and DL. Samples from rat aortas were prepared as described in "Methods". Values 
represent the mean ± SEM of 4 rat aortas from each group.
Δ = difference between the MYPT1 phosphorylation measured in the absence of drug addition and that obtained in the presence of indicated 
ROCK1 inhibitors.
The effect of HA-1077 on angiotensin-II induced contraction in aortic strips isolated from n rmoglycemic (group N), in vivo losar an treated normoglyce ic (group NL), diabetic (group D) and in vivo l sartan treated diabeti  rats (group DL)Figu e 4
The effect of HA-1077 on angiotensin-II induced con-
traction in aortic strips isolated from normoglycemic 
(group N), in vivo losartan treated normoglycemic 
(group NL), diabetic (group D) and in vivo losartan 
treated diabetic rats (group DL). Cumulative concentra-
tion-response curves of angiotensin-II (bolus) were per-
formed on 100 nM phenylephrine (Phe) pre-contracted 
thoracic aortic strips stretched to 0.7 g resting tension with 
an endothelial-intact layer and pre-incubated with 10 μM 
HA-1077. The contraction obtained with 100 nM Phe was set 
as 100%. The insert shows the decrease in contraction 
(reported as mg/mg of tissue w.w., absolute value) obtained 
with HA-1077 on angiotensin-II-induced (1 μM) contracture. 
Values are the mean ± SEM of 4 experiments. ***P < 0.001 
vs. all other groups; §§§P < 0.01 vs. N and D groups.
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aortas (Table 4).
ROCK1 protein expression: the effect of losartan
To investigate whether over-activation of ROCK1 might
be the consequence of ROCK1 over-expression, we per-
formed a Western-blot analysis of aortic proteins. Our
results, presented in Figure 5 (upper panel), show that the
level of ROCK1 expression were indeed higher in aortas
from D when compared to that of N and NL (P < 0.05 vs.
N and NL, figure 5 bottom panel). Furthermore, as for the
functional data, the expression of ROCK1 lowered in con-
sequence of losartan treatment. In fact, in DL aortas, the
expression of ROCK1 was similar to that found in N and
NL aortas (Figure 5, bottom panel).
Discussion
Our data demonstrate that aortas isolated from 2-week
STZ rats present hyper-contracture to AT-II, but not to the
alpha1-agonist Phe, and that this hyper-response is par-
tially prevented by an in vivo treatment with losartan. In
fact, in diabetic aortas, AT-II efficacy of contracture was
higher (hyper-contracture) than that in aortas from nor-
moglycemic rats and in vivo losartan treated diabetic rats.
The effect of AT-II in diabetic aortas, occurs at conditions
of conserved vasorelaxant capacity to acetylcholine, in
line with data obtained in a similar early model of STZ-
rats [25], and in the absence of any significant change in
systemic pressure (Table 2) suggesting that endothelial
dysfunction might not be functionally measurable at our
experimental settings.
Analyzing the concentration-response curves, we con-
cluded that the augmented AT-II intrinsic activity found in
diabetic aortas was not the consequence of increasing AT-
II receptor levels. In fact, pharmacological evidence indi-
cated that in aortas from all the groups of rats: 1) AT-II
maintained a similar potency at 20, 50 and 80% of its
maximum effect in determining contracture; 2) irbe-
sartan, as well as irbesartan plus PD123319, reduced anal-
ogously AT-II contracture. These results confirmed that
the contribution of AT1 and AT2 in determining AT-II
hyper-contracture was similar in aortas from normo and
hyperglycemic rats. To note, a residual, AT1 and AT2
antagonist-insensitive contracture, whose extent was
again similar in normo and hyperglycemic aortas, was
measurable. This residual contracture, might result from
the release of some contractile factor(s) induced by AT-II
or from the presence of an AT-II receptor with a low sus-
ceptibility to irbesartan and PD123319 both used at selec-
tive and effective concentrations [32,33].
From all these data, we concluded that the increased
response to AT-II in diabetic aortas could be explained by
an over-activation of some transduction system(s) cou-
pled to AT-II receptors.
Being the hyper-contracture to AT-II reduced in DL group,
we hypothesised that the in vivo AT1 receptor activation
might play a fundamental role in determining AT-II effect
in diabetic aortas.
Since the ROCK1 system is among the effectors of the AT1
cascade, we explored its involvement in AT-II hyper-con-
tracture. To this aim we verified the AT-II effect in N, NL,
D and DL aortas exposed to HA-1077. Our result showed
that HA-1077 did not affect AT-II contracture in normo-
glycemic aortas (N and NL groups), whereas it strongly
reduced the AT-II contraction in D and DL groups (-22.1
± 2.25 and -11.4 ± 1.32 mg/mg tissue w. w. respectively at
the 1 μM AT-II). In the presence of HA-1077, diabetic aor-
tas responded to AT-II similarly to normoglycemic ani-
mals. Increased ROCK1 signalling, in terms of protein
ROCK1 expression in aorta homogenates from normoglyc-emic (grou  N), in vivo l sartan-treated normoglyce ic (group NL), diabetic (gr up D) and in vivo losartan treated diabetic rats (group DL)Figure 5
ROCK1 expression in aorta homogenates from nor-
moglycemic (group N), in vivo losartan-treated nor-
moglycemic (group NL), diabetic (group D) and in 
vivo losartan treated diabetic rats (group DL). Upper 
panel: ROCK1 protein expression level evaluated by West-
ern-blot (a representative experiment is shown). Lower 
panel: densitometric analysis of bands normalized to actin 
expression. Three gels were analyzed and results represent 
the mean ± SEM of 3 experiments. *P < 0.05 vs. all other 
groups.
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Cardiovascular Diabetology 2009, 8:32 http://www.cardiab.com/content/8/1/32expression and enzyme activity, was also demonstrated in
diabetic aortas where ROCK1 protein expression and its
activity were two and around 2–3 times higher respec-
tively than that measured in N and NL rats. These results
showed quite a good correlation between ROCK1 protein
expression/activity with functional data.
It is also noteworthy that, among the kinases able to phos-
phorylate MPT/MYPT1, only ROCK1 activity was up-regu-
lated in our diabetic aortas.
Interestingly, ROCK1 expression and activity were signifi-
cantly lower in DL than in D aortas. This allowed us to
conclude that in vivo losartan treatment corrected diabetic
AT-II hyper-contracture, preventing the increase in
ROCK1 expression and activity. The association between
AT-II hyper-response and ROCK1 was corroborated by the
evidence that HA-1077 did not modify Phe contractility,
likely for the different Gprotein subtypes activated by the
two agonists. Indeed, RhoA/ROCK1 activation is mainly
dependent on G12/13 protein-linked AT1 [1], while other
G proteins are less effective in this pathway. Other authors
have reported a low involvement of RhoA/ROCK1 path-
way in alpha adrenergic stimulation [22,34]. Indeed,
alpha1-contracture was unchanged in our experimental
groups as already described elsewhere [25].
Accumulating evidence spotlight on RhoA/ROCK1 signal-
ling as a critical regulator in determining Ca2+ sensitiza-
tion of the vascular smooth muscle cells contractile
machinery [10,22,30-36]. In line with this, ROCK1 has
attracted significant interest as a potential target for the
treatment of a wide range of pathological conditions
including cancer, neuronal degeneration, kidney failure,
asthma, glaucoma, osteoporosis, erectile dysfunction,
insulin resistance and its cardiovascular complications
[37]. Despite the considerable interest and the develop-
ment of potent ROCK1 inhibitors, there is little informa-
tion on clinical trials with selective ROCK1 inhibitors
[37]. On the contrary, numerous clinical trials have exten-
sively confirmed the efficacy and safety of losartan and
other AT1 blockers in diabetic and or hypertensive
patients [38,39].
Although the STZ-rat is one among the experimental
models of diabetes, it shows suitability for studying the
basic mechanisms of diabetic cardiovascular complica-
tions and their time-dependent progression [25]. Thus,
our data obtained on a model of "early diabetes", could
suggest a new molecular mechanism supporting the pro-
tective role of losartan in diabetic vascular complications.
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